Abstract
Symptom provocation has proved its worth for understanding the pathophysiology of diseases and in general for the development of new therapeutic approaches in the medical field. In the research of anxiety disorders, investigations using experimentally induced panic attacks by various agents, such as sodium lactate, carbon dioxide, cholezystokinine-tetrapetid etc., have a long tradition and allow the exploration of usually naturally occuring spontaneous psychopathological phenomena under controlled conditions. Post-Traumatic Stress Disorder (PTSD) is a prevalent disorder that can develop following exposure to an extreme traumatic event. In DSM-IV it is currently classified as an anxiety disorder and shares phenomenological similarities with panic disorder. The use of panicogenic challenge tests is also an interesting neurobiological approach to learn more about the nature of PTSD and may be a possibility to develop new therapeutic strategies for the treatment of PTSD symptoms. Not only panic anxiety, but also flashbacks and other dissociative symptoms can be provoked by several panicogens in PTSD. The purpose of this review is to evaluate studies using panicogens in PTSD. Methodological short-comings of current studies and needed directions of further research are discussed.
Keywords: PTSD, panic, panicogen, flashback, lactate, CCK-4, CO2, flumazenil, m-CPP, yohimbine
Current Pharmaceutical Design
Title:Panicogens in Patients with Post-Traumatic Stress Disorder (PTSD)
Volume: 18 Issue: 35
Author(s): Christoph Muhtz, Klaus Wiedemann and Michael Kellner
Affiliation:
Keywords: PTSD, panic, panicogen, flashback, lactate, CCK-4, CO2, flumazenil, m-CPP, yohimbine
Abstract: Symptom provocation has proved its worth for understanding the pathophysiology of diseases and in general for the development of new therapeutic approaches in the medical field. In the research of anxiety disorders, investigations using experimentally induced panic attacks by various agents, such as sodium lactate, carbon dioxide, cholezystokinine-tetrapetid etc., have a long tradition and allow the exploration of usually naturally occuring spontaneous psychopathological phenomena under controlled conditions. Post-Traumatic Stress Disorder (PTSD) is a prevalent disorder that can develop following exposure to an extreme traumatic event. In DSM-IV it is currently classified as an anxiety disorder and shares phenomenological similarities with panic disorder. The use of panicogenic challenge tests is also an interesting neurobiological approach to learn more about the nature of PTSD and may be a possibility to develop new therapeutic strategies for the treatment of PTSD symptoms. Not only panic anxiety, but also flashbacks and other dissociative symptoms can be provoked by several panicogens in PTSD. The purpose of this review is to evaluate studies using panicogens in PTSD. Methodological short-comings of current studies and needed directions of further research are discussed.
Export Options
About this article
Cite this article as:
Muhtz Christoph, Wiedemann Klaus and Kellner Michael, Panicogens in Patients with Post-Traumatic Stress Disorder (PTSD), Current Pharmaceutical Design 2012; 18 (35) . https://dx.doi.org/10.2174/138161212803530817
DOI https://dx.doi.org/10.2174/138161212803530817 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Individual Differences and Vulnerability to Drug Addiction: A Focus on the Endocannabinoid System
CNS & Neurological Disorders - Drug Targets Spirituality, Religiosity and Addiction Recovery: Current Perspectives
Current Drug Research Reviews The Challenges of Chemical Stability Testing of Herbal Extracts in Finished Products Using State-of-the-Art Analytical Methodologies
Current Pharmaceutical Analysis The Potential Impact of Sirtuin 1 Protein on Premature Ovarian Insufficiency
Current Proteomics Group I Metabotropic Glutamate Receptor Interacting Proteins: Fine-Tuning Receptor Functions in Health and Disease
Current Neuropharmacology Exploring N<sup>1</sup>-p-Fluorobenzyl-Cymserine as an Inhibitor of 5-Lipoxygenase as a Candidate for Type 2 Diabetes and Neurodegenerative Disorder Treatment
CNS & Neurological Disorders - Drug Targets Microglia-Neuron Interaction in Inflammatory and Degenerative Diseases: Role of Cholinergic and Noradrenergic Systems
CNS & Neurological Disorders - Drug Targets Psychotic Denial of Pregnancy
Current Women`s Health Reviews Different Concepts of Drug Delivery in Disease Entities
Mini-Reviews in Medicinal Chemistry Apathy Is not Associated with Performance in Brief Executive Tests in Patients with Mild Cognitive Impairment and Mild Alzheimers Disease
Current Alzheimer Research Sensory Perception Abnormalities in People at Clinical High-Risk for Psychosis and Those with First-Episode Psychosis
Current Psychiatry Reviews Roles of Nicotinic Acetylcholine Receptors in Stem Cell Survival/Apoptosis, Proliferation and Differentiation
Current Molecular Medicine A Case-Control Study Investigating the Effect of MTHFR C677T Variant on Performance of Elite Athletes
Endocrine, Metabolic & Immune Disorders - Drug Targets Scutellaria barbata Flavonoids Improve the Composited Aβ-induced Abnormal Changes in Glial Cells of the Brains of Rats
Combinatorial Chemistry & High Throughput Screening Curcumin and Immunity
Current Bioactive Compounds VIP and Drug Design
Current Pharmaceutical Design NPY Y2 and Y4 Receptors Selective Ligands: Promising Anti-Obesity Drugs?
Current Topics in Medicinal Chemistry Hepatic Effects of Duloxetine-II: Spontaneous Reports and Epidemiology of Hepatic Events
Current Drug Safety Criteria of Evidence to Move Potential Chemopreventive Agents into Late Phase Clinical Trials
Current Drug Targets In vitro Study of Furazano[3,4-b]quinoxaline 1-Oxides as Potential ΝΟ Releasing Agents
Letters in Drug Design & Discovery